TABLE 4.

Posttransplant cPRA, HLA antibody, and DSA

Subject	Posttransplant maximum cPRA	Anti-HLA Ab persistent de novo	Renal DSA persistent de novo	Islet DSA persistent de novo	Islet graft failure
1	7	No	No	No	No
2	5	Yes	No	No	No
6	46	Yes	No	No	Yes
7	26	Yes	No	No	Yes
8	56	Yes	No	Yes	Yes
10	75	Yes	No	Yes	Yes
12	0	No	No	No	No
20	8	Yes	No	No	No
22a	96	No	No	No	Yes
23b	0	Weak	Weak	Weak	Yes
24c	0	Weak	Weak	No	No

Abbreviations: DSA, donor specific antibody; cPRA, calculated PRA; MFI, mean fluorescence intensity; PHPI, purified human pancreatic islets.

^aAnti-HLA antibodies developed while the subject was on the waiting list with the pretransplant cPRA increasing to 96%. This result was not available at the time of islet transplantation, and the subject received a PHPI product in the presence of a shared kidney and islet DSA.

^bWeak HLA class I DSA (HLA-A2, 600-800 MFI) developed posttransplant to the kidney and first islet donor. In addition, weak DSA were directed to the kidney and second islet cell donor (DQ7,8,9, 200-1000 MFI). These antibodies were below the predetermined threshold for positivity.

^cPossible weak renal DSA developed posttransplant to HLA-DQ5,6 (MFI value in the 200-1800) which was below the predetermined threshold for positivity.